+44 7868 792050
Bone disease in myeloma patients result from the exaggerated osteoclast activity and suppression of osteoblast function in the myelomatous bone marrow and is responsible for most serious complications of myeloma. The bone anabolic effects of bortezomib with 1.3 mg/m2 and 1 mg/m2 dosages have been previously reported. In this study, we for the first time examined the effect of Bortezomib 0.7 mg/m2 dose on bone metabolic parameters in six patients with relapse MM. Even with the low dose used in the trial, we observed increase in the PTH levels in 50% of treated patients and parallel changes in osteocalcin levels, suggesting osteoblastic activation. To our knowledge, this is the first report of bone anabolic effects of bortezomib associated proteasome inhibition at such small doses.